Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Fenel Eloi
AddedMar 31, 2024
UpdatedMay 1, 2026
Fenel Eloi

Fenel Eloi

Board Member, Standard BioTools

Fenel Eloi's Career

Standard BioTools
Standard BioTools

South San Francisco, CA, US

Board Member· Board
Ultivue
Ultivue

Cambridge, MA, US

Board Member· Board
Vaxess Technologies
Vaxess Technologies

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Fenel Eloi's Career

Standard BioTools
Standard BioTools
Public$375.2M5231999South San Francisco, CA, US
Board Member· Board

Leadership at Standard BioTools

Michael EgholmMichael EgholmCEO
Carlos PayaCarlos PayaBoard Member
Gajus WorthingtonGajus WorthingtonFounder
Martin MadausMartin MadausBoard Member
Gerhard F. Burbach, MBAGerhard F. Burbach, MBABoard Member
Ultivue
Ultivue
Series D$107.3M562015Cambridge, MA, US
Board Member· Board

Leadership at Ultivue

Ralf JungmannRalf JungmannCo-Founder
Keith CrandellKeith CrandellBoard Member
David WaltDavid WaltCo-Founder
Peng YinPeng YinCo-Founder
Adam WieschhausAdam WieschhausBoard Member
Rob CarsonRob CarsonCEO

Similar to Ultivue

Altos LabsAltos LabsRedwood City, CA, USCell Therapiesest. 2021Altos LabsRedwood City, CA, US · est. 2021

Altos Labs, Inc.: An American biotech firm pioneering life extension therapies via specialized cell therapies since 2022.

Series A · $3B500
Zinnia TechnologiesZinnia TechnologiesChicago, IL, USCare Toolsest. 2019Zinnia TechnologiesChicago, IL, US · est. 2019

Zinnia Technologies: A leading care tool provider, offering rewarding careers and a balanced work-life culture.

Pre-Seed · $120k6
ClearLight BiotechnologiesClearLight BiotechnologiesSunnyvale, CA, US3D Imaging, Tissue Analysisest. 2015ClearLight BiotechnologiesSunnyvale, CA, US · est. 2015

ClearLight Biotechnologies: Innovating non-destructive 3D tissue analysis for clinical research.

Seed · $12.3M11
Upstream BioUpstream BioWaltham, MA, USAntibody Therapyest. 2021Upstream BioWaltham, MA, US · est. 2021

Upstream Bio: Clinical-stage developer of monoclonal antibody therapy for severe asthma.

Series B · $408M17
Vaxess Technologies
Vaxess Technologies
Series A$74.9M422011Cambridge, MA, US
Board Member· Board

Leadership at Vaxess Technologies

Vicki SatoVicki SatoBoard Member
Livio ValentiLivio ValentiCo-Founder
Aaron SandoskiAaron SandoskiBoard Member
Purnanand SarmaPurnanand SarmaBoard Member
Patrick HoPatrick HoCo-Founder
Johannes FruehaufJohannes FruehaufBoard Member

Fenel Eloi's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Fenel Eloi

Jacqualyn FouseJacqualyn FouseBoard Member · CelgeneSandra ShotwellSandra ShotwellBoard Member · Elex BiotechHarry WilcoxHarry WilcoxBoard Member · BG MedicineAnthony ShuberAnthony ShuberFounder · Exact SciencesAndrew J. LastAndrew J. LastBoard Member · OncocyteNelson FonsecaNelson FonsecaBoard Member · Easy Solutions